HMGB1 ‐Induced Metabolic Rewiring of Macrophages via RAGE / MAPK Fosters Endocrine Resistance in Breast Cancer
Immunology · 2026
DOI: 10.1111/imm.70182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, 2026. Verfasst von Donglin Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China. Hauptthemen laut MEDLINE: HMGB1 Protein, Breast Neoplasms, Macrophages, Receptor for Advanced Glycation End Products. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Regional Joint Key Project of National Natural Science Foundation of China, General Program of National Natural Science Foundation of China, Key Research and Development Program Project of Heilongjiang Province.
Abstract (Originalsprache)
Endocrine resistance remains a critical challenge in hormone receptor‐positive (HR+) breast cancer. The impact of the immune microenvironment on endocrine therapy efficacy is increasingly recognised, but its mechanisms are not fully understood. Here, we investigated that nuclear HMGB1 expression in tumour cells was closely associated with endocrine therapy resistance in HR+ breast cancer using tumour genomic databases. Specially, tumours with high HMGB1 expression induced M2‐like macrophage polarisation, which was related to HMGB1 paracrine signalling. Mechanistically, HMGB1 bound to the RAGE receptor on macrophages, activating the downstream MAPK signalling pathway and was closely linked to the activation of fatty acid metabolism pathways. Macrophages co‐cultured with high‐HMGB1 tumour cells exhibited metabolic characteristics associated with carcinogenesis, a loss of glycolytic intermediates and a shift toward a pro‐tumourigenic metabolic state compared to those co‐cultured with low‐HMGB1 cells. Co‐culture with M2‐like macrophages significantly activated growth signalling pathways like NF‐κB in the high‐HMGB1 tumour cells. Taken together, high expression of HMGB1 in tumour cells promotes fatty acid metabolic remodelling and functional polarisation in macrophages, contributing to endocrine therapy resistance in HR+ breast cancer. HMGB1 acts as a candidate for immune mediator and paved a way to develop potential target drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China.
ORCID-Profile: Donglin Liu, Yuwei Deng, Qingyuan Zhang
Förderung
- Regional Joint Key Project of National Natural Science Foundation of China
- General Program of National Natural Science Foundation of China
- Key Research and Development Program Project of Heilongjiang Province
Zitieren
APA
Liu, D., Sun, S., Peng, J., Shi, S., Deng, Y., & Zhang, Q. (2026). HMGB1 ‐Induced Metabolic Rewiring of Macrophages via RAGE / MAPK Fosters Endocrine Resistance in Breast Cancer. Immunology. https://doi.org/10.1111/imm.70182
Vancouver
Liu D, Sun S, Peng J, Shi S, Deng Y, Zhang Q. HMGB1 ‐Induced Metabolic Rewiring of Macrophages via RAGE / MAPK Fosters Endocrine Resistance in Breast Cancer. Immunology. 2026. doi:10.1111/imm.70182
BibTeX
@article{Liu2026,
author = {Liu, Donglin and Sun, Shengnan and Peng, Junning and Shi, Shuling and Deng, Yuwei and Zhang, Qingyuan},
title = {HMGB1 ‐Induced Metabolic Rewiring of Macrophages via RAGE / MAPK Fosters Endocrine Resistance in Breast Cancer},
journal = {Immunology},
year = {2026},
doi = {10.1111/imm.70182}
}
EUVIMED